| Business Summary | | IntraBiotics
Pharmaceuticals,
Inc.
develops
and
intends
to
commercialize
novel
antibacterial
and
anti-fungal
drugs
for
the
prevention
or
treatment
of
serious
infectious
diseases.
The
Company's
clinical
and
development
programs
focus
on
solving
medical
problems
for
patients
who
have
few
or
no
satisfactory
alternatives.
Because
of
their
bacteria-
or
fungi-killing
mechanisms,
the
Company's
drug
candidates
are
designed
to
be
useful
in
fighting
microorganisms
that
are
resistant
to
traditional
antibiotics. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IntraBiotics
Pharmaceuticals,
Inc.
develops
and
intends
to
commercialize
novel
antibacterial
and
antifungal
drugs
for
the
prevention
or
treatment
of
serious
infectious
diseases.
For
the
three
months
ended
3/31/01,
the
Company
reported
no
revenues.
Net
loss
totalled
$18.7
million,
up
from
$7.3
million.
Revenues
reflect
the
absence
of
product
and
contract
sales.
Higher
loss
reflects
an
increase
in
personnel
and
payroll
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
after
tax
earnings
were
-34,314. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Kenneth Kelley, 42 Chairman,
Pres, CEO | $380K | $326K | Sandra Wrobel, 41 CFO,
VP, Bus. Operations | 235K | 129K | Donna Caley, 56 VP
of Organization Devel. | -- | -- | Henry Fuchs, M.D., 43 VP,
Clinical Affairs | 250K | 133K | Chee-liang Leo Gu, Ph.D., 50 VP,
Pharmaceutical Devel. | 190K | 105K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|